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Journal of the American Heart Association
CONTEMPORARY REVIEW

Stroke–Heart Syndrome: Recent Advances
and Challenges
Jan F. Scheitz , MD; Luciano A. Sposato , MD; Jeanette Schulz-Menger, MD; Christian H. Nolte
Johannes Backs, MD; Matthias Endres , MD

, MD;

ABSTRACT: After ischemic stroke, there is a significant burden of cardiovascular complications, both in the acute and chronic
phase. Severe adverse cardiac events occur in 10% to 20% of patients within the first few days after stroke and comprise a
continuum of cardiac changes ranging from acute myocardial injury and coronary syndromes to heart failure or arrhythmia.
Recently, the term stroke– heart syndrome was introduced to provide an integrated conceptual framework that summarizes
neurocardiogenic mechanisms that lead to these cardiac events after stroke. New findings from experimental and clinical
studies have further refined our understanding of the clinical manifestations, pathophysiology, and potential long-term consequences of the stroke–heart syndrome. Local cerebral and systemic mediators, which mainly involve autonomic dysfunction
and increased inflammation, may lead to altered cardiomyocyte metabolism, dysregulation of (tissue-resident) leukocyte populations, and (micro-) vascular changes. However, at the individual patient level, it remains challenging to differentiate between
comorbid cardiovascular conditions and stroke-induced heart injury. Therefore, further research activities led by joint teams
of basic and clinical researchers with backgrounds in both cardiology and neurology are needed to identify the most relevant
therapeutic targets that can be tested in clinical trials.
Key Words: brain–heart axis ■ heart ■ inflammation ■ outcomes ■ stroke
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schemic stroke patients are at substantial risk of heart
disease, and, vice versa, heart disease increases
the risk of ischemic stroke. Randomized controlled
trials and observational studies reported severe adverse cardiac events in ≈10% to 20% of patients with
acute ischemic stroke.1–7 These clinically severe cardiac complications are more common in patients with
severe stroke and may even occur in patients without
known comorbid cardiac disease.1,2,4,6 Stroke patients
with early severe cardiac complications are at a 2-to
3-fold increased risk of short-term mortality.1,8 Beyond
these acute neurocardiogenic alterations, the occurrence of cardiovascular events and cardiac death are
the main drivers of long-term prognosis after stroke.9,10
Nearly one-third of deaths in stroke survivors can be
attributed to a cardiac cause.10,11 Both short-term and
long-term cardiac events after stroke happen despite
contemporary secondary prevention measures. Thus,
there is a medical need to reduce the burden of both

acute and long-
term cardiovascular complications
after stroke.
Within the past years, it is increasingly recognized
that the interactions between heart disease and ischemic stroke are more than a mere consequence of traditional vascular risk factors that affect both organs. Based
upon the evidence from preclinical and clinical studies
that acute ischemic stroke can have immediate deleterious effects on the heart, the concept of a distinct stroke–
heart syndrome was introduced in 2018 (see Box and
Figure 1 for definition).1,3,12–15 The intention of the concept
was to provide an integrated view of stroke-related cardiac complications to increase the clinical awareness,
generate a common mechanistic framework, and facilitate the development of research collaborations and
clinical management pathways. The stroke–heart syndrome concept summarizes the full spectrum of cardiac changes newly observed within the first 30 days
after an acute ischemic stroke.3,7 Its pathophysiological
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model views ischemic stroke as a specific event triggering neurocardiogenic heart injury and is based on both
preclinical and clinical data suggesting a strong overlap
between the continuum of clinical phenotypes and underlying mechanisms.1,3 The biggest controversy around
this concept relates to the underlying pathophysiologic
mechanisms: Is cardiac dysfunction following ischemic
stroke caused by vascular comorbidity along the cardiovascular risk continuum, is it a specific event triggered by
the stroke, or both? On an individual patient level, physicians are challenged by the clinical problem whether
acute cardiac injury in a patient with stroke represents
a critical event requiring urgent cardiac diagnostics and
potentially harmful intervention.
In this review, we aimed to provide an updated
overview of the experimental phenotype and clinical
manifestations of the stroke–heart syndrome, and to
extend the existing pathophysiological model, focusing
on the most relevant stroke characteristics, key mediators, as well as downstream cardiac signaling pathways. Finally, we aimed to derive the most challenging
questions and promising directions for future research.

MANIFESTATIONS OF STROKE–HEART
SYNDROME
Evidence From Animal Models
Rodent models of experimental stroke provide a unique
opportunity to study both the immediate short-term and

longer-term effects of ischemic stroke on the heart. In
the late 1980s and early 1990s, there was an initial period of flourishing animal research on deleterious heart–
brain interactions following stroke. Ground-
breaking
experiments in cats and rats demonstrated that stroke
can impair physiological autonomic cardiac function
and provoke proarrhythmogenic electrocardiographic
designed
changes.16,17 In recent years, several well-
experimental studies have helped to refine our knowledge of the stroke–heart syndrome phenotype in rodent models (Figure 2).18–24 To study the acute cardiac
effects of stroke, Veltkamp and colleagues induced
an experimental ischemic stroke via transient (60 minutes) filament occlusion of the left middle cerebral artery (MCAo) in mice.18 This paradigm resulted in large
cerebral infarcts and was paralleled by early cardiac
dysfunction and damage. Serial echocardiographic
measurements showed that MCAo reduced left ventricular (LV) ejection fraction and LV fractional shortening by 10% to 15% as compared with sham-operated
animals. These effects began on the first day after
experimental stroke and persisted for up to 14 days.
These findings were accompanied by myocardial injury
as reflected by transiently 3-to 5-fold increase in levels
of high-sensitivity cardiac troponin (hs-cTn), bradycardia, rapid cardiomyocyte atrophy, and cardiac weight
loss.18 Vornholz and colleagues were able to reproduce
this phenotype of acute cardiac dysfunction also after
right-sided MCAo.19 A similar study in rats demonstrated that embolic strokes resulting in large brain infarcts and severe neurologic deficits induced early and
persistent reduction in LV fractional shortening.23
Beyond these immediate cardiac effects, there
is evidence that ischemic stroke produces a chronic
heart failure phenotype. Bieber and colleagues performed short-term, right-sided MCAo in mice resulting
in small ischemic lesions in the basal ganglia and the
rodent analogue of the insular cortex.21 Eight weeks
after surgery, MCAo resulted in a significant reduction
of LV ejection fraction of about 15% compared with
sham-operated and control animals. This was accompanied by a significantly higher heart rate, increased LV
end-systolic and end-diastolic volumes, cardiac hypertrophy, and adverse cardiac remodeling as measured
by increased LV collagen content.21 Similarly, in several
murine stroke models that induced right-sided small
to intermediate cortical lesions, a progressive 10% to
25% reduction in LV ejection fraction was found over a
3-day to 4-week period along with cardiac interstitial fibrosis.20,22,24 There is evidence that cardiac alterations
are not limited to the left ventricle, but also include the
left atrium. In a rat model with selective ischemic lesions of the left and right insular cortex stroke by local
endothelin-1 injection, stroke resulted in left atrial remodeling and fibrosis, particularly in atrial regions with
rich autonomic innervation.25
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Updated Criteria and Features of the Stroke–Heart Syndrome*

Clinical definition
• New evidence of cardiac alterations or documented worsening of premorbid cardiac function after ischemic stroke.
Clinical phenotype†
• Acute myocardial injury (elevation of cardiac troponin with rise/fall pattern).
• Acute coronary syndrome (via coronary demand ischemia or coronary plaque destabilization).
• Left ventricular systolic and diastolic dysfunction including Takotsubo syndrome secondary to stroke.
• ECG changes (especially repolarization disorders like QTc prolongation), cardiac arrhythmias, and atrial fibrillation detected after stroke.
• Sudden cardiac death.
Time course
• Cardiac alterations usually peak within 72 hours after ischemic stroke onset and are considered to be part of stroke–heart syndrome if they
occur within 30 days after the index event.
• Potential long-term consequences of stroke–heart syndrome occur later than 30 days after stroke.
Risk factors
• General: age, burden of cardiovascular risk factors.
• Stroke-specific: stroke severity, involvement of central autonomic network (especially the insular cortex).
• Heart specific: preexisting coronary or structural heart disease.
Differential diagnoses
• Other systemic or cardiac conditions: in particular sepsis, chronic but stable heart failure, pulmonary embolism, pulmonary hypertension,
acute kidney injury, chronic kidney disease, myocarditis, and recent cardiac intervention.
• Causes of coronary demand ischemia not directly attributable to stroke (eg, anemia and reduced blood oxygenation).
Recent key advances
• Animal models established and characterized an acute and chronic phenotype of stroke-induced cardiac dysfunction.
• More clinical evidence supports a time-dependent trajectory of poststroke cardiac events with a highest prevalence (10%–20%) within the
time-frame of 30 days after stroke.
• More evidence supports the role of systemic and local cardiac inflammation as drivers of stroke–heart syndrome.
• More clinical evidence supports that patients with stroke–heart syndrome are at increased risk of long-term major cardiac events.
*Adapted from Scheitz et al and Sposato et al.1,3 †Note that manifestations may overlap in the individual patient.
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A potential drawback of animal research is that experimental stroke models usually use young, male, and
healthy animals.18,25,26 This may hamper translation into
clinical practice, because ischemic stroke is typically
a disease of the elderly with a high burden of chronic
cardiovascular comorbidities.27,28 To improve clinical
translation, international guidelines recommend repeating experiments in aged and animals of both sexes
as well as animals with comorbidities such as diabetes
or hypertension.29 Of note, there is evidence that the
stroke–heart syndrome is more pronounced in diabetic
mice and similar in young and aged mice.20,21,30 This
underscores the notion that modeling the stroke–heart
syndrome in rodents can be achieved under clinically
relevant conditions. If these aspects are further considered in the future, streamlined rodent models will
remain highly valuable tools to probe neurocardiogenic
mechanisms of stroke–heart syndrome, identify causal
mediators, and test promising interventions.

Spectrum, Severity, and Time Course of
Clinical Manifestations
The stroke–
heart syndrome encompasses a broad
clinical spectrum of cardiovascular changes including
(1) acute myocardial injury (as evidenced by acute elevation of hs-cTn), (2) acute coronary syndromes (ACS; including type 1 and type 2 myocardial infarction [MI]), (3)

systolic and diastolic LV dysfunction including Takotsubo
syndrome (TTS), (4) cardiac arrhythmias including atrial
fibrillation (AF) and relevant ECG changes, and (5)
neurogenic sudden cardiac death (Box, Figure 2).1,3
Importantly, these categories are not mutually exclusive,
and there is substantial overlap between these manifestations.1,31,32 Established risk factors include older age,
premorbid cardiac disease, and stroke characteristics
such as stroke severity, infarct size, and lesion site in
the insular cortex.1,2 The stroke–heart syndrome apparently affects women and men equally, although certain
phenotypes, such as TTS secondary to stroke, mainly
affect women.33–35 In the original description of the
stroke–heart syndrome, we proposed the differentiation
of stroke–
heart syndrome from myocardial ischemia
because of coronary plaque rupture or plaque thrombosis (ie, type 1 MI). Recent evidence from experimental studies in humans and mice, however, suggest that
acute mental stress and neuroinflammation may lead to
destabilization of atherosclerotic plaques via activation
of the neuroendocrine axis and subsequent uptake of
inflammatory leucocyte populations.36,37 Thus, we now
propose that also type 1 MI may occur as part of the
spectrum of the stroke–heart syndrome. Given the high
frequency of atypical clinical presentation of ACS in the
elderly, especially those with neurological deficits (such
as aphasia), the accurate diagnosis of ACS has to rely
on strict and systematic clinical examination, typical
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The Stroke-Heart Syndrome – Recent Advances and challenges
Stroke-Heart Syndrome
Definition:
New evidence of cardiac
alterations or documented
worsening of premorbid
cardiac function after
ischemic stroke
Manifestations:
ECG changes, arrhythmia
Myocardial injury, ACS
Heart Failure, Takotsubo
Sudden cardiac death
Frequency:
10-20% cardiac SAE
within 30 days
Time-Course:
Peak within 72 hours
up to 30 days.

Prognosis:
2-3 fold increased risk of shortterm mortality
1.5-2 fold increased risk of
MACE during long-term
Risk factors:
Age, pre-morbid heart disease,
stroke-specific factors (severity,
insular cortex)
Pathophysiology:
Autonomic dysbalance
and inflammation
Stroke-induced ‚cardiac
stress test‘
Perspectives:
Join forces to identify treatments
(basic/ clinical scientists;
neurologists/ cardiologists/
immunologists)
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Figure 1. Summary of key criteria and of the stroke–heart syndrome.
ACS indicates acute coronary syndrome; MACE, major adverse cardiovascular events; and SAE, severe adverse events.

ECG findings, and cardiac imaging showing regional
wall-motion abnormalities or coronary lesions.3,38
With the introduction of increasingly sensitive and
specific cardiac diagnostic tests within the past decades, it became clear that the manifestations of the
stroke–heart syndrome range from oligo-or even asymptomatic laboratory or ECG findings to severe clinical manifestations requiring urgent cardiac diagnostics
and treatments. The most common cardiac changes
include myocardial injury (ie, elevated hs-
cTn levels
above assay-specific reference limits), ECG alterations
such as QTc prolongation, and LV diastolic dysfunction, which are observed in up to 60% of patients with
acute ischemic stroke, typically during the initial in-
hospital workup.8,31,38 These patients are at increased
risk of death and more likely to leave the hospital with
more severe stroke-
related disabilities.8,39 Because
the individual premorbid cardiac status is usually unknown, thorough clinical assessment and serial diagnostic tests are required to distinguish comorbid
and clinically stable heart disease from stroke–heart
syndrome. Several observational studies documented

that myocardial injury and prolonged QTc time are associated with the incidence of more severe forms of
stroke–heart syndrome.2,4,32,39–41 Therefore, it is reasonable and also recommended by current guidelines
to measure hs-cTn and perform a standard 12-lead
ECG to screen for subclinical early cardiac involvement after ischemic stroke.42 In case of pathological
findings, prolonged ECG monitoring, thorough clinical cardiac assessment, and serial measurement of
hs-cTn are warranted to identify patients at higher risk
of developing severe or fatal cardiovascular complications. Data from systematic evaluations of adverse
events documented in high-quality randomized controlled trial settings have shown that 10% to 20% of
patients with acute ischemic stroke suffer a severe
cardiac adverse event requiring urgent evaluation and
treatment.2,5–7 These mainly include acute myocardial
injury (characterized by a distinctive rise or fall pattern
of hs-cTn levels),8,38,43 LV systolic dysfunction,31,40,44,45
and arrhythmia including atrial fibrillation.4,46 In 1%
to 5% of patients, even more severe manifestations,
such as myocardial infarction,5,47,48 overt heart failure
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Figure 2. Phenotypes and time course of the stroke–heart syndrome in rodent models and clinical practice.
(Top) Phenotype observed in rodent ischemic stroke models. The dashed blue line indicates physiological cardiac function. The red
line indicates the severity of acute cardiac dysfunction that peaks within 24 to 72 hours and persists up to 14 days after experimental
stroke. Note that this phenotype was most consistently inducible by severe brain ischemia. The black line indicates a phenotype of
chronic cardiac dysfunction starting 4 to 8 weeks after experimental brain ischemia. Note that this phenotype was most consistently
inducible by mild, right-sided brain ischemia. (Bottom) Spectrum and time-course of stroke–heart syndrome observed in human
clinical studies. The dashed blue line indicates physiological trajectory of cardiac function during aging. The blue line indicates the
trajectory of cardiac alterations after stroke observed in observational clinical studies. Note that there is large individual variability, and
that further studies are needed to predict the incidence of long-term cardiovascular outcomes and heart failure. EF indicates ejection
fraction; HF, heart failure; LV, left ventricular; and MACE, major adverse cardiovascular events.

including TTS,1,3,7,34,45 and malignant tachycardia or
cardiac arrest, have to be expected.4,5,7 The spectrum
of severe forms of stroke–heart syndrome are associated with a 2-to 3-fold increased risk of mortality or
poor functional outcome.1,5,48
In regard to the time course, there is evidence that
the acute manifestations of the stroke–heart syndrome
peak within the first 72 hours after brain ischemia
(Figures 1 and 2)1,2,4 but may not be limited to this early
phase. A recent Canadian population-based study of
adults aged ≥66 years, 9.1% of 21 931 patients with
first-ever ischemic stroke had incident major adverse
cardiovascular events (MACE) at 1 year (including ACS
and MI, coronary interventions, incident congestive
heart failure, or cardiovascular death).9 Compared
with 71 696 matched individuals without stroke or
heart disease, ischemic stroke was associated with a
4.5-times higher risk of MACE. Of note, patients with
known heart disease at baseline were excluded from

this study, and the increased risk was strongly time
dependent.9,33 Although adjusted risk of MACE was
increased 25-fold in the first 30 days, it remained >2
times higher during the first year after ischemic stroke.9
Based on this time-dependent trajectory, it can be assumed that MACE occurring within the first 30 days
after stroke may be directly attributable to the stroke–
heart syndrome.3 After this phase, incident MACE and
heart failure can be considered as possible long-term
consequences of the initial cardiac injury attributable
to stroke–heart syndrome.

Current Challenges
It remains challenging to differentiate whether poststroke cardiac events are manifestations of stroke–
heart syndrome, an expression of an underlying
cardiac condition, or both. This is because the cardiac
status before the stroke is usually not known when the
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patient presents to the emergency department and
because systematic cardiac evaluations by performing serial echocardiography or cardiovascular magnetic resonance (CMR) imaging during follow-
up of
stroke are lacking. As outlined above, however, there is
strong evidence supporting a potential causal relationship between stroke and subsequent cardiac complications. In addition to the wealth of animal data that
show experimental stroke can induce immediate and
chronic cardiac dysfunction,13,18,22 clinical data provide
evidence that there is a time-dependent occurrence
of cardiac complications with a clear peak during the
first few days after stroke.1,2,4,9,35 Major adverse cardiac events are also observed even when patients
with known history of heart disease are excluded.9,49
Further evidence comes from observational studies
that applied coronary angiography in stroke patients
with elevation of hs-cTn, showing that the majority of
these patients had no underlying obstructive coronary artery disease.47,50 Serial measurements of hs-
cTn demonstrate a rise or fall pattern in 15% to 30%
of patients,8,43 which means that myocardial injury is
acute and not chronic in these patients. Finally, specific
stroke characteristics like stroke severity and stroke lesion site promote the occurrence of poststroke cardiac
events even when statistically accounting for premorbid cardiac conditions.32,41,51,52 These stroke characteristics linked to stroke–heart syndrome are discussed in
more detail below.
To date, it remains also challenging to determine
whether long-
term vascular events and post-
stroke
cognitive dysfunction are prompted by stroke–heart
syndrome or whether premorbid subclinical heart
disease, or both, accounts for the observed associations. However, there is increasing evidence that this
might be the case. As described earlier, a phenotype
of chronic cardiac dysfunction with myocardial fibrosis can be induced 4 to 8 weeks after experimental
stroke.21,24 Moreover, ex vivo experiments using rat
hearts derived from animals that underwent an experimental stroke paradigm were more susceptible to
second ischemic hits to the heart.23 This suggests an
increased susceptibility to secondary cardiac events
poststroke. This presumption is supported by a recent retrospective analysis using a global (primarily US
based) network of 365 383 health care records of patients with stroke and 5-year follow-up that compared
the long-term cardiovascular outcomes of stroke patients with and without manifestations of stroke–heart
syndrome (defined as new-onset cardiovascular complications within 30 days after stroke).7 Patients with
stroke–
heart syndrome had a 1.5-to 2-
fold higher
odds of 5-year mortality and MACE depending on the
respective manifestation of stroke–heart syndrome.7
Although this study focused on substantial manifestations of stroke–heart syndrome diagnosed based on

Stroke–Heart Syndrome: Advances and Challenges

International Classification of Diseases (ICD-10) codes,
there is also evidence that more subtle manifestations may entail a higher cardiovascular risk. In a clinical study of 201 ischemic stroke patients, those who
had evidence of autonomic imbalance (ie, lower high-
frequency power in heart-rate variability analysis) within
48 hours after stroke had a higher risk of secondary
ischemic events within 90 days.53 However, most of
the events detected in this study occurred early after
stroke, highlighting the need for more confirmative data
with regard to the longer term. Of 220 patients with
first-ever, mild-to-moderate ischemic stroke and myocardial injury measured with hs-cTn within a median of
4 days after the event, but without clinical diagnosis of
concurrent ACS, 27.3% experienced a cumulative end
point of recurrent stroke, MI, or death within 3 years
of follow-up.54 This was significantly higher than in
the control group of 342 patients with normal hs-cTn
levels during the acute poststroke phase (10.2%; adjusted hazard ratio, 2.0).54 Beyond the occurrence of
cardiovascular events, there is also evidence that patients with (subclinical) myocardial injury in the acute
phase after the ischemic stroke have a higher burden
of cerebral small vessel disease and cognitive impairment than those without.55,56 Among 555 patients with
first-ever ischemic stroke, global cognitive impairment
was present in 43% of patients with hs-
cTn values
in the highest quartile.56 This proportion was significantly higher than in the group of patients with hs-cTn
in the lowest quartile (15%) and remained statistically
significant after adjusting for potential confounders.
Cognitive function remained worse in this group during
the 3 years of follow-up.56
Another challenging field of research includes the
entity of AF detected after stroke (AFDAS), which may
be considered a particular expression of the stroke–
heart syndrome. According to a meta-analysis, previously unknown AF can be found in ≈10% of patients
with ischemic stroke during the initial in-
hospital
workup and in ≈25% by sequentially combining cardiac monitoring methods during long-term follow-up.46
The theoretical construct of AFDAS has evolved in recent years and addresses its distinctive characteristics when compared with AF known before stroke.57,58
Conceptually, AFDAS results from the interplay of underlying cardiogenic mechanisms and stroke-related
neurogenic phenomena.58 AFDAS seems to have a
lower prevalence of cardiovascular comorbidities and
less severe structural heart disease than AF known before stroke occurrence.58,59 These findings may explain
why patients with AFDAS seem to have a lower risk
of stroke recurrence than those with a known history
of AF before stroke onset.60,61 AFDAS probably encompasses higher and lower risk phenotypes based
on the severity of preexisting atrial cardiopathy and
the prevalence of risk factors.58 Within the spectrum
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of AFDAS risk, patients with severe atrial cardiopathy
(eg, dilated left atrium) are those who may bear the
higher risk, whereas those with structurally healthy
hearts and lower-
burden AFDAS triggered by self-
limited and short-lasted neurogenic mechanisms may
have a lower embolic risk.3,62,63 Studies combining biomarkers, neuroimaging patterns, and cardiovascular
comorbidities are needed to further characterize higher-and lower-risk AFDAS phenotypes. Characterizing
these phenotypes may help improve the selection of
ischemic stroke and transient ischemic attack patients
who could benefit more from anticoagulation if AFDAS
is found on prolonged cardiac monitoring.

PATHOPHYSIOLOGY OF
STROKE–HEART SYNDROME
The pathophysiological model of stroke–
heart syndrome considers the spectrum of clinical manifestations to be the result of neurocardiogenic mechanisms
leading to stroke-induced heart injury (stroke-induced
cardiac stress-test).1,3 Of note, neurocardiogenic injury
is not restricted to an ischemic stroke cause and can
be observed in other acute brain disorders such as
seizures, traumatic brain injury, and intracranial hemorrhage (reviewed elsewhere).64 Within the past few

years, further advances have been made that have
helped to further elucidate the complex interplay of ischemic stroke-lesion characteristics, local cerebral and
systemic mediators, and downstream cardiac mechanisms leading to the stroke–heart syndrome (Figure 3).
The next paragraphs summarize these advances and
describe promising future directions of research.

Impact of Stroke Characteristics
There is evidence that specific localizations of the ischemic lesion favor the occurrence of stroke–
heart
syndrome. A well-studied example is the association
between ischemic lesions in the insular cortex and the
occurrence of acute myocardial injury, TTS, and arrhythmia.8,34,41,51,52 In experimental studies, the extent
of histological damage in the correlate of the insula in
the mouse brain damage correlated with the severity
of cardiac dysfunction and troponin elevation.19,26 The
insular cortex is an integral part of central autonomic
network (CAN) and is involved in both cardiac interoception and efferent cardiovascular response to emotional experience.65,66 Under physiological conditions,
the CAN regulates sympathetic and parasympathetic
neuronal outflow to the heart.3,66 Ischemic stroke may
lead to abrupt changes in the physiological organization of the CAN, resulting in autonomic dysfunction.
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Stroke

Mediators

Heart

Outcome

Immunological
• Brain-bone marrowspleen signals
• Systemic Inflammation
• Inflammasome

High risk of

Neuronal
• Autonomic nervous
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• Cardiovascular events
Downstream Mechanisms

Stroke characteristics
• Lesion size, stroke severity
• Central autonomic network
changes

• Heart failure
• Cardiac death
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• Catecholamines
• Cortisol
• Vasoactive mediators
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• Brain derived
death factors
• miRNAs
• Extracellular vesicles
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Cardiomyocyte
injury
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Figure 3. Overview about stroke-specific characteristics, mediators, downstream cardiac mechanisms, and outcomes of
stroke–heart syndrome.
The 4 columns describe the most promising and well-studied stroke characteristics, mediators, cardiac mechanisms, and short-term
and long-term outcomes of stroke–heart syndrome.
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Importantly, the occurrence of the stroke–heart syndrome is not limited to ischemia within the insular
cortex. Both in clinical and experimental settings, a
phenotype of poststroke cardiac dysfunction can also
be observed when the insular cortex itself is not affected.22,24,67 Other relevant regions of the CAN with
documented impact on cardiac function include the
amygdala, anterior cingulate cortex, ventromedial prefrontal cortex, hypothalamus, mediodorsal thalamus,
hippocampus, and brainstem regions.3,66,68–70 With regard to the latter, QTc prolongation on ECG upon hospital admission was found in 9 out of 12 patients with
acute medullary infarction.71 Lesion mapping revealed
that QTc prolongation correlated with lesions in the
right or left dorsal vagal nucleus. Remarkably, QTc time
partially normalized during the in-hospital stay, suggesting a causal relationship with the stroke event. In
addition, lateral medullary infarction can occasionally
result in central sleep-
related hypoventilation, which
may lead to secondary cardiac injury (eg, via endothelial dysfunction) or coronary demand ischemia.72,73 Of
note, stroke lesion sites in the insula and brain stem
are associated with sleep-disordered breathing during
the early poststroke phase.74 In turn, sleep-disordered
breathing after stroke was linked to impaired cardiac
autonomic dynamics, endothelial dysfunction, ECG alterations like sinus brady-or tachycardia, and reduced
LV function.73–75 Therefore, the interplay between the
CAN and sleep-disordered breathing and its potential
impact on the occurrence of the stroke–
heart syndrome deserves further study.
Recent evidence from patients with TTS (synonymous with stress cardiomyopathy) highlights the role
of the CAN in the occurrence of cardiac dysfunction.
Compared with healthy controls, a surface-and voxel-
based morphometry study revealed that patients
with TTS related to emotional stress but unrelated to
acute stroke have reduced cortical thickness in both
insulae and reduced amygdala volume.76 Moreover, a
functional magnetic resonance imaging study demonstrated altered parasympathetic and sympathetic network activity in TTS patients versus matched controls.77
In a case–control study of 104 individuals undergoing
positron emission tomography–
computed tomography imaging, higher activity in the amygdala was associated with the occurrence of TTS during a median
follow-up of 2.5 years.78 Interestingly, individuals with
the highest activity within the amygdala developed TTS
up to 2 years earlier than those with relatively lower activity.78 Of note, higher resting activity of the amygdala
and higher perceived stress was associated with arterial inflammation, bone marrow activity, and incident
cardiovascular events in patients without known cardiovascular or cerebrovascular disease.79 However, it
remains challenging to determine whether inherited or
acquired (eg, by epigenetic mechanisms) disturbance
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of stress response and function of the CAN well before the stroke increase the individual’s susceptibility
to develop stroke–heart syndrome. Moreover, further
clinical studies (eg, using lesion-network mapping approaches) are needed to determine the specificity of
CAN dysfunction (beyond the insula and brain stem) for
the occurrence of the stroke–heart syndrome.
Beyond specific lesion sites, observational clinical
data provide compelling evidence that stroke severity
is associated with the occurrence of virtually all manifestations of the stroke–heart syndrome.1 This association has been shown most consistently in relation to
the occurrence of myocardial injury, cardiac arrhythmia, and impaired LV function after stroke.4,8,60,67 In line
with this data, animal studies provided evidence that
the severity of acute and chronic cardiac dysfunction
correlates with the size of brain ischemia.18,21,26 Larger
ischemic brain injury not only increases the likelihood
of CAN dysfunction, but also leads to more profound
disruption of the blood–brain barrier and damage to
the neurovascular unit. As a result, danger signals and
extracellular vesicles enter the bloodstream, which results in a systemic activation of the immune system.80
This is in line with the notion that the extent of cerebral
injury and inflammation correlate with detrimental effects on the heart. Whether this can be targeted by
therapeutic interventions remains to be proven.

Key Mediators
The knowledge about critical mediators of the stroke–
heart syndrome is rather scarce. However, the way
toward mechanistic studies is paved by combining experimental animal models such as MCAo with
deeper cardiac phenotyping. Sympathetic overdrive
and reduced parasympathetic activity as a cause for
cardiac dysfunction in the stroke–heart syndrome are
among the most consistently discussed mediators.1,3,81
MCAo-induced cardiac dysfunction in mice was associated with higher levels of norepinephrine in serum
and the heart and linked to peripheral sympathetic
overactivity.21,26 Seemingly contradicting, cardiac norepinephrine stores were enhanced 3 days after MCAo
in the study of Veltkamp and colleagues, which could
be interpreted as a decrease in sympathetic activity
3 days after stroke.18 However, unbiased RNA microarray analyses showed massive changes in expression
of catecholamine-driven genes in the latter experimental setup. This suggests an early sympathetic overactivation in the heart persisting for at least 1 but not for
3 days after MCAo. In line with these considerations,
it has been shown that already 2 hours after cerebral
embolism in rats, circulating catecholamines were increased along with a reduction in cardiac function.23
Therefore, local cardiac catecholamine homoeostasis
should, in particular, be examined and targeted in the
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first hours after ischemia in the brain. Of note, MCAo-
induced cardiac dysfunction could be attenuated by
β-blockers.21 Moreover, different experiments found
that monoamine oxidase inhibition resulted in both reduced local cerebral neuroinflammation and reduced
catecholamine-induced cardiac dysfunction.82,83 This
points to the potential of neuro-humoral blockade as
therapeutic target. The role of autonomic dysfunction is
supported by clinical evidence of impaired autonomic
reflexes, and variability of blood pressure and heart
rate in patients with ischemic stroke.84–86 High blood
pressure variation, especially within the first 3 hours
in the early critical phase of autonomic disbalance is
associated with increased mortality at 90 days.87 Both
tachycardia and hypertensive blood pressure levels
are established triggers of coronary demand ischemia,
which can cause myocardial injury.88 In addition, pressure overload can lead to reversible LV dysfunction
with troponin release and myocyte apoptosis even
without necrosis.89
Recent experimental studies support an important role of inflammatory responses in the occurrence
of stroke–heart syndrome.19,24 Stroke-induced cardiac
dysfunction in mice was accompanied by a systemic
inflammatory response, upregulation of proinflammatory
cytokines within the myocardial tissue, and macrophage
infiltration into the heart.19,24 Thus, besides sympathetic
overactivation, proinflammatory pathways represent independent or perhaps interdependent mediators of the
stroke–heart syndrome. In regard to the latter, sympathetic activation leads to the mobilization of inflammatory
cells from the bone marrow or spleen.90,91 In a photothrombotic stroke model, splenectomy attenuated cardiac dysfunction along with interstitial cardiac fibrosis
at 4 weeks.24 This was preceded by an attenuation of
proinflammatory cytokines and cardiac macrophage recruitment, suggesting that the spleen is critically involved
in the development of subacute and long-term consequences of stroke–heart syndrome, eventually leading
to chronic remodeling. Beyond the brain–bone marrow–
spleen axis, further interorgan cross talks that involve the
kidney and gut may be relevant drivers of inflammation
and promote poststroke cardiac injury.92,93
The directed recruitment of CD45+ leukocytes
to the heart in response to injury has been shown
to depend on cardiomyocyte-born cardiokines that
serve as chemoattractant signaling molecules.94,95
Although the specific role of these cardiomyocyte-
born signals in stroke–heart syndrome remains to be
shown, similar pathophysiological roles have already
been described for CC-chemokine ligands 2 (monocyte chemotactic protein 1) and 3 (macrophage inflammatory protein) in ischemia–
reperfusion injury
of the heart.94,95 Importantly, this cascade was mediated by a catecholamine-sensitive protein kinase,
namely CaMKII (Ca2+/calmodulin-dependent kinase II)
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in cardiomyocytes, pointing to a model in which both
peripheral sympathetic activation along with local cardiac sympathetic activation collectively orchestrate
myocardial inflammation. Another candidate mediator
in this particular context is BDNF (brain-derived neurotrophic factor), a neurotrophin involved in the development of (autonomic) neurons, angiogenesis, and
maintenance of endothelial function.96,97 It has been
demonstrated that BDNF improves cardiac muscle
contraction and relaxation via the before-mentioned
CaMKII pathway.97 Circulating levels of BDNF are reduced after stroke, especially after severe stroke.98
Therefore, BDNF signaling may represent a pathway
mediating the interplay between autonomic tone, endothelial integrity, and myocardial dysfunction. Further
experimental stroke studies in this direction are warranted in the future.
Both systemic inflammation and sympathetic overdrive can result in activation of coagulation, platelet
hyperactivity, and endothelial dysfunction.99–101 This
process of thromboinflammation has received scientific
attention during the COVID-19 pandemic and has been
proposed as an important mediator of myocardial injury, coronary microcirculatory dysfunction, and other
extrapulmonary manifestations of COVID-19.101,102 The
impact of thromboinflammation in the occurrence of
the stroke–heart syndrome, however, has yet to be
proven.
A potential contribution of cell–
cell communication in combination with proinflammatory signals
have recently been shown in experimental stroke
models. Stroke-induced cardiac fibrosis and LV dysfunction was accompanied by decreased levels of
the microRNA miR-126 in the serum and the heart.22
Mice specifically lacking miR-126 in endothelial cells
showed an even more severe phenotype. This study
demonstrates how a stroke-associated reduction in
miR-126 and miR126-target genes may mediate the
stroke–heart syndrome via the involvement of endothelial cells. Thus, it is possible that vascular injury
after stroke might lead to long-distance cell–cell communication independent of the surrounding tissue.
In this regard, metabolites or extracellular vesicles
should also be considered.103 Of note, administration
of exosomes derived from cluster of differentiation
133+ umbilical cord blood cells attenuated cardiac
dysfunction in a photothrombotic stroke model.20
This was accompanied by reduced oxidative stress,
reduced transforming growth factor-beta expression,
and reduced recruitment of proinflammatory macrophages. cluster of differentiation 133+ umbilical cells
express miR-
126, thereby providing a potential link
to the aforementioned endothelial mechanism. The
vasculature, with its enormous surface, may thereby
serve as an amplifier of deleterious signals as was recently demonstrated in tumor biology.104
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The above-mentioned mediators affect various cardiac
cell populations via induction of coronary demand ischemia (eg, via coronary vasoconstriction), microvascular dysfunction, metabolic switches, and cardiac
inflammation (Figure 2). Within the past years, it is increasingly recognized that cardiomyocytes constitute
less than half of the total cardiac cell population.105 In
response to acute injury, other cardiac-resident cells,
including fibroblasts as well as the vasculature and
immune cell compartments, also undergo phenotype
changes that can trigger maladaptive cardiac remodeling. Interestingly, it has been shown that tissue-
resident cardiac macrophages can be activated by
remote injury processes including stroke.106 Several
downstream cardiac pathways have been established
to mediate cardiac dysfunction.107 However, signaling
pathways to be potentially targeted by pharmacologic
interventions that mediate acute cardiac dysfunction
after stroke are largely elusive. Previous approaches
to use calcium sensitizers in stroke models failed,108
indicating that the underlying pathways may be more
complex. Evidence for an important contribution of
pro-
inflammatory pathways was provided by a recent study in which an inhibitor of NLRP3 (NLR family
pyrin domain containing 3), a key component of the
inflammasome, restored cardiac function in mice after
MCAo.30 In a rat stroke model, increased oxidative
stress and altered NO signaling were measured in the
left atria. This was accompanied by the recruitment of
neutrophils, T and B lymphocytes into the left atrium,
as well as atrial fibrosis.25 A detailed analysis of the
recruitment of proinflammatory cells, receptor-ligand
binding studies in combination with single cell, or even
single nucleus sequencing may add to a better mechanistic understanding of these processes and their role
in reducing the burden of stroke–heart syndrome.
In addition, recent discoveries highlight the role of
the interface between metabolic and epigenetic processes. Nr4a1 (nuclear receptor subfamily 4 group a
member 1) is a catecholamine-
sensitive nuclear receptor that integrates cytokine signaling in inflammatory disorders by acting in nonmyocytes.109 Nr4a1 was
found to be upregulated 1 day after MCAo in the heart.18
Interestingly, Nr4a1 was also enhanced in cardiomyocytes derived from induced pluripotent stem cells of
TTS patients,110 suggesting an overlapping molecular
signature of these 2 brain-dependent forms of acute
cardiac dysfunction. Interestingly, Nr4a1 was shown
to be a key target of an epigenetic axis affecting cardiomyocyte calcium handling in response to stress.111
Mechanistic experiments revealed that this process
was causative for exercise-
induced cardiac fatigue,
which is reminiscent of the stroke–heart syndrome.
Thus, it will be interesting to explore the potential
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contribution of these epigenetic-
metabolic signaling
pathways to the stroke–heart syndrome. Supporting
this notion, many of the genes acutely regulated after
experimental stroke were found to depend on the activity of the transcription factor PPARα (peroxisome
proliferator-activated receptor α) that regulates fatty
acid storage and glucose metabolism.18
Besides upregulation of metabolic pathways,
Veltkamp and colleagues also reported that pathways
that mediate muscle wasting were regulated following
experimental stroke.18 These expression changes persisted over >3 days, pointing to more long-term consequences. Likewise, heart weight was reduced in the
first days after MCAo, suggesting that these changes
might impact the heart, resulting in pathological atrophy, a process that is also seen in muscle wasting
diseases such as cancer-related cachexia. However,
data that investigate the potential causal involvement
are missing but may represent another new research
direction.

OPEN QUESTIONS, ONGOING
STUDIES, AND DIRECTIONS FOR
FUTURE RESEARCH
Currently, there are many unanswered questions on
the pathophysiology, long-term outcomes, and specific therapeutic approaches to stroke–
heart syndrome, with many of them being addressed in ongoing
studies (Table).40,67,112–120 Because elevation of serum
markers of myocardial injury is associated with all other
clinical categories of stroke–heart syndrome,4,32,40,41 it
seems reasonable to measure hs-cTn in all patients
to screen for early cardiac involvement after ischemic
stroke and identify patients who are at risk for a more
severe clinical course and further specific cardiac diagnostics. As described above, it is currently not clear
how to differentiate causes of myocardial injury at the
individual patient level and identify patients at high risk
of ACS requiring timely coronary revascularization. It
is therefore crucial to refine diagnostic algorithms to
identify the corresponding underlying pathophysiology
in the respective patient, in the future ideally without invasive diagnostics. This question is currently being answered by the PRAISE (Prediction of Acute Coronary
Syndrome in Acute Ischemic Stroke) study, in which
stroke patients with relevant hs-cTn elevation undergo
coronary angiography in addition to standardized
electrocardiography and echocardiographic assessment.119 In the future, other suitable diagnostic measures may routinely involve contrast-enhanced multislice
cardiac computed tomography and/or comprehensive
CMR to differentiate cardiac pathologies.121,122 In particular, CMR offers opportunities to distinguish causes

J Am Heart Assoc. 2022;11:e026528. DOI: 10.1161/JAHA.122.02652810

Atrial
Cardiomyopathy
in Patients
With Stroke of
Undetected
Mechanism112
(NCT03830983)

BEHABIS (The Bern
Heart and Brain
Interaction Study)67
(NCT03720522)

BeLOVE (Berlin
Long-Term
Observation of
Vascular Events)113
(DRKS00016852)

CONVINCE
(Colchicine
for Prevention
of Vascular
Inflammation in
Non-CardioEmbolic
Stroke)115
(NCT02898610)

CORONA-IS
(Cardiomyocyte
Injury Following
Acute Ischemic
Stroke)116
(NCT03892226)

Heart and Brain
Study–Substudy
of Whitehall II
Imaging cohort117
(NCT03335696)

2

3

4

5

6

Title of study
(registration)

1

Study
Copenhagen,
Denmark

Bern, Switzerland

Berlin, Germany

Several countries in
Europe

Berlin, Germany

Oxford, United
Kingdom

Prospective,
observational,
single-center
cohort study
Prospective,
observational,
multicenter cohort
study

Randomized
controlled trial
(colchicine vs
placebo)

Prospective,
observational,
single-center
cohort study

Prospective,
observational,
cohort study

City, country

Prospective,
observational,
case–control-study
(healthy age-and
sex-matched
controls)

Design

Retired British civil
servants

Acute ischemic
stroke with hospital
admission <48 h
after symptom
onset

Noncardioembolic
ischemic stroke
without major
disability

Hospitalization for:
acute ischemic
stroke; acute
coronary syndrome,
acute heart failure,
acute kidney injury
(4 study arms)

Acute ischemic
stroke (<12 h after
symptom onset)
without severe renal
failure (GFR <40)

Ischemic stroke
(≤30 d before
inclusion) without
atrial fibrillation

Target population

775

300

2623

10 000, 2000 each
study arm

220

150 (originally
estimated
enrolment=225)

Target no. of
patients

Brain atrophy,
cognitive decline

Quantify autonomic
dysfunction
and decipher
downstream
cardiac
mechanisms
leading to
myocardial injury

Recurrence of
nonfatal ischemic
stroke, nonfatal
major cardiac
event, vascular
death

MACE
(cardiovascular
mortality, nonfatal
stroke, nonfatal
myocardial
infarction,
hospitalization
because of heart
failure)

TTS (prevalence of
neurogenic stunned
myocardium),
subacute MI

Extent of LA fibrosis
incidence of silent
brain lesions, LA
volume, LAEF

Outcomes of
interest

Ongoing Clinical Studies Exploring the Pathophysiology or Targeting of Long-Term Consequences of Stroke–Heart Syndrome
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Vascular
ultrasound, MRI
(head)

Multimodal CMR,
echocardiography,
autonomic
ECG markers,
biobanking

Clinical assessment

Clinical
assessment, CMR,
MRI (head), ECG,
3-dimensional
echocardiography,
ocular coherence
tomography

CMR (gadolinium-
enhanced with or
without perfusion)

Gadolinium-
enhanced CMR
imaging

Measures

(Continued)

Recruitment
completed,
extended follow-up

Active, recruiting

Active recruiting

Active, recruiting

Active, recruiting

Active, recruiting

Progress
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InsuCor (Insular–
Noninsular Stroke
Underlying
Cardiac Failure
(DRKS00012454)

MIRACLE (MR
Evidence of Cardiac
Inflammation Post-
Stroke Study)

Multifactorial Risk
Stratification in
Patients With
Ischemic Stroke
or Transient
Ischemic Attack
and Structural,
Inflammatory, or
Arrhythmogenic
Cardiac Disease118
(NCT04352790)

PRAISE (Prediction
of Acute Coronary
Syndrome After
Acute Ischemic
Stroke)119
(NCT3609385)

Predicting the
Development
of Myocardial
Depression in
Acute Neurological
Patients
(NCT03801694)

PROSCIS
(Prospective Cohort
With Incident
Stroke)120
(NCT01363856,
NCT01364168)

8

9

10

11

12

Title of study
(registration)

7

Study

Continued

Berlin (PROSCIS-B);
Munich
(PROSCIS-M),
Germany

Prospective,
observational,
hospital-based
cohort study

Multicenter,
Germany

Prospective,
observational,
multicenter cohort
study

Columbus, Ohio,
USA

Tübingen, Germany

Prospective,
observational,
single-center
cohort study

Prospective,
observational
single-center
cohort study

London, Ontario,
Canada

Würzburg,
Germany

City, country

Prospective,
observational,
cohort study

Prospective,
observational,
case–control study

Design

First ever acute
stroke (including
intracerebral
hemorrhage in
Berlin)

Female patients
with acute ischemic
stroke or patients
with SAH, >50 y,
predicted to be
on norepinephrine
infusion for at least
48 h

Acute ischemic
stroke (<72 h) with
troponin elevation

Ischemic stroke
or TIA admitted to
hospital

Acute ischemic
embolic stroke
of undetermined
source

Acute ischemic
stroke (onset <3 d;
with and without
involvement of the
insular lobe)

Target population
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627 with first-ever
ischemic stroke
(Berlin), 850
(Munich)

10

251

878

44

180

Target no. of
patients

Composite of
stroke, myocardial
infarction, and
vascular death
(within 3 y)

Stress-induced
cardiomyopathy

Presence of
acute coronary
syndrome, deaths,
functional outcome,
cardiovascular
events

Any stroke,
mortality, ischemic
stroke, TIA,
systemic embolism,
myocardial
infarction,
intracranial
hemorrhage, major
bleeding

NT-proBNP,
systemic
inflammation,
myocardial
infarction, LV
function, LA fibrosis

(New) systolic
cardiac
dysfunction, stroke,
vascular events
within 3 mo

Outcomes of
interest

Clinical follow-up
including cerebral
MRI, cognitive
testing

ST-T changes
on ECG,
echocardiography
and measurement
of catecholamines
and troponin

Coronary
angiography,
echocardiography,
ECG

Clinical follow-up

NT-proBNP,
inflammatory
markers,
gadolinium
enhanced CMR
imaging

Echocardiography,
blood biomarker

Measures

(Continued)

Recruitment
completed (Berlin);
active (Munich).

Active and
recruiting

Recruitment
completed.
Follow-up ongoing

Active, not
recruiting

Active, recruiting

Active, recruiting

Progress

Scheitz et al
Stroke–Heart Syndrome: Advances and Challenges

J Am Heart Assoc. 2022;11:e026528. DOI: 10.1161/JAHA.122.02652812

CMR indicates cardiovascular MRI; LA, left atrium; LAEF, left atrial ejection fraction; LV, left ventricle; MACE, major adverse cardiovascular events; MI, myocardial infarction; MR, magnetic resonance; MRI, magnetic
resonance imaging; NT-proBNP, N-terminal pro-B-t ype natriuretic peptide; SAH, subarachnoid hemorrhage; TIA, transient ischemic attack; and TTS, Takotsubo syndrome.

Recruitment
completed. First
results published.
Follow-up by mail
or telephone,
echocardiography
and ECG
Heart failure,
manifestation of
cardiovascular
disease
696
Würzburg,
Germany
SICFAIL (Stroke-
Induced Cardiac
Failure in Mice and
Men)40
(DRKS00011615)
14

Prospective,
observational,
single-center
cohort study

Acute ischemic
stroke with
treatment on stroke
unit

Active and
recruiting
Remote ischemic
conditioning (brief
and transient limb
ischemia)
Any death and
recurrence of
cardiac and
cerebrovascular
ischemic events
within 3 mo
80
Acute ischemic
stroke (onset <24 h)
plus acute coronary
syndrome (onset
<24 h), elderly
patients (≤60 y)
Beijing, China
Randomized,
controlled, double-
blind, trial (sham
procedure)

Measures
Study

Table.

Continued

RIC-ACS
(Protective Effects
of Remote Ischemic
Conditioning in
Elderly With Acute
Ischemic Stroke
Complicating
Acute Coronary
Syndrome)
(NCT03868007)

Outcomes of
interest
Target no. of
patients
Target population
Design

City, country
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of myocardial injury after stroke and investigate long-
term cardiac remodeling. The localization, pattern, and
estimated reversibility of myocardial tissue changes
enables the differentiation of ischemic and nonischemic injury. Focal fibrosis, as detected by CMR, may
reflect unrecognized MI and has a prognostic impact
in suspected ischemic heart disease.123 Beyond focal
fibrosis, diffuse fibrosis can be quantified by CMR and
strongly correlates with histopathological findings of
collagen content in the myocardium.124 Diffuse fibrosis on CMR is associated with ventricular remodeling
and event-free survival in patients aortic stenosis.125
The role of CMR to differentiate mechanisms of myocardial injury after stroke is being addressed in the
CORONA-
IS (Cardiomyocyte Injury Following Acute
Ischemic Stroke) study.116
Further open questions concern in particular the
longer-term outcomes of stroke patients with stroke–
heart syndrome, especially with regard to chronic cardiac function and vascular end points. At present, it is
not clear if the high frequency of systolic and diastolic
dysfunction detected in stroke patients is transient and
recovers over time or whether this will result in clinically
manifest heart failure. Approximately one-third of patients with early poststroke cardiac dysfunction have
known heart failure before the stroke.45 More longitudinal clinical studies are needed to determine the time-
course, reversibility, and progression of heart failure in
stroke patients. Among others, the SICFAIL (Stroke-
Induced Cardiac Failure in Mice and Men) study aims
to characterize and provide mechanistic understanding for long-term cardiac dysfunction after stroke.40
The biggest task for the future will be to prove how to
specifically treat stroke–heart syndrome and its long-
term consequences. From our point of view, it seems
conclusive that stroke patients with ACS should primarily be treated with coronary revascularization.126,127
In contrast, patients with other manifestations of
stroke–heart syndrome may benefit from a pathophysiologically oriented drug therapy. This could consist
of targeting the sympathetic nervous system (eg, with
β-
blockers), heart rate control, and improvement of
blood pressure variability (eg, β-blockers, ivabradine,
renin–angiotensin system inhibitors), anti-inflammatory
approaches (eg, inhibition of the inflammasome or inflammatory cytokines like interleukin-1β with colchicine
or canakinumab), improvement of vascular endothelial
function, and reduction of oxidative stress (eg, with
statins, renin–
angiotensin system inhibitors, antioxidants, new generation monoamine oxidase inhibitors),
a combined antithrombotic medication (eg, temporary
use of dual antiplatelets or adding low-dose anticoagulation), and avoiding proarrhythmic drugs (QTc prolongation). Until now, however, none of these candidates
have formally been tested in appropriate randomized
and blinded therapy studies. Joint research initiatives
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led by interdisciplinary teams of cardiologists and neurologists from both preclinical and clinical perspectives
are needed to reduce the knowledge gap and improve
the clinical management of stroke-associated cardiac
complications.
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